WO2021022067A8 - Parvovirus antibodies for veterinary use - Google Patents

Parvovirus antibodies for veterinary use Download PDF

Info

Publication number
WO2021022067A8
WO2021022067A8 PCT/US2020/044302 US2020044302W WO2021022067A8 WO 2021022067 A8 WO2021022067 A8 WO 2021022067A8 US 2020044302 W US2020044302 W US 2020044302W WO 2021022067 A8 WO2021022067 A8 WO 2021022067A8
Authority
WO
WIPO (PCT)
Prior art keywords
parvovirus
antibodies
various embodiments
parvovirus antibodies
canine
Prior art date
Application number
PCT/US2020/044302
Other languages
French (fr)
Other versions
WO2021022067A3 (en
WO2021022067A2 (en
Inventor
Hangjun Zhan
Lam Nguyen
Ellen RATCLIFF
Richard Chin
Shyr Jiann Li
Original Assignee
Kindred Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences, Inc. filed Critical Kindred Biosciences, Inc.
Priority to CA3143785A priority Critical patent/CA3143785A1/en
Priority to US17/630,685 priority patent/US20220267414A1/en
Priority to JP2022505401A priority patent/JP2022542275A/en
Priority to MX2022001104A priority patent/MX2022001104A/en
Priority to EP20847060.9A priority patent/EP4004035A4/en
Priority to CN202080066883.XA priority patent/CN114466862A/en
Priority to BR112022000249A priority patent/BR112022000249A2/en
Priority to KR1020227003757A priority patent/KR20220071176A/en
Priority to AU2020321376A priority patent/AU2020321376A1/en
Publication of WO2021022067A2 publication Critical patent/WO2021022067A2/en
Publication of WO2021022067A3 publication Critical patent/WO2021022067A3/en
Publication of WO2021022067A8 publication Critical patent/WO2021022067A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and/or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods to prevent and/or treat parvoviral infection in subjects, such as dogs and cats. For example, the parvovirus antibodies provided may be used to provide passive immunity against infection with a canine or feline parvovirus.
PCT/US2020/044302 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use WO2021022067A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA3143785A CA3143785A1 (en) 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use
US17/630,685 US20220267414A1 (en) 2019-07-30 2020-07-30 Parvovirus Antibodies for Veterinary Use
JP2022505401A JP2022542275A (en) 2019-07-30 2020-07-30 veterinary parvovirus antibody
MX2022001104A MX2022001104A (en) 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use.
EP20847060.9A EP4004035A4 (en) 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use
CN202080066883.XA CN114466862A (en) 2019-07-30 2020-07-30 Parvovirus antibody for animals
BR112022000249A BR112022000249A2 (en) 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use
KR1020227003757A KR20220071176A (en) 2019-07-30 2020-07-30 Parvovirus Antibodies for Veterinary Use
AU2020321376A AU2020321376A1 (en) 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962880650P 2019-07-30 2019-07-30
US62/880,650 2019-07-30
US202062968970P 2020-01-31 2020-01-31
US62/968,970 2020-01-31
US202063030123P 2020-05-26 2020-05-26
US63/030,123 2020-05-26

Publications (3)

Publication Number Publication Date
WO2021022067A2 WO2021022067A2 (en) 2021-02-04
WO2021022067A3 WO2021022067A3 (en) 2021-07-15
WO2021022067A8 true WO2021022067A8 (en) 2021-10-14

Family

ID=74229890

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/044302 WO2021022067A2 (en) 2019-07-30 2020-07-30 Parvovirus antibodies for veterinary use

Country Status (10)

Country Link
US (1) US20220267414A1 (en)
EP (1) EP4004035A4 (en)
JP (1) JP2022542275A (en)
KR (1) KR20220071176A (en)
CN (1) CN114466862A (en)
AU (1) AU2020321376A1 (en)
BR (1) BR112022000249A2 (en)
CA (1) CA3143785A1 (en)
MX (1) MX2022001104A (en)
WO (1) WO2021022067A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220064224A1 (en) * 2018-11-13 2022-03-03 Novobind Livestock Therapeutics, Inc. Antibodies against disease causing agents of canines and felines and uses thereof
CN116735873B (en) * 2023-08-09 2023-10-31 北京纳百生物科技有限公司 Application of monoclonal antibody specifically binding to canine parvovirus VP2 protein in detection reagent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4263951B2 (en) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 Methods for making and using caninized antibodies
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
WO2012164372A1 (en) * 2011-06-01 2012-12-06 Indian Immunologicals Limited Recombinant anti-canine parvovirus antibody and uses thereof
ES2687129T3 (en) * 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Compositions and methods to evaluate the functional immunogenicity of parvovirus vaccines
CN104364264B (en) * 2012-06-06 2018-07-24 硕腾服务有限责任公司 Dog source anti-ngf antibodies and its method
GB201404503D0 (en) * 2013-07-09 2014-04-30 Mars Inc Canine health product
AU2015280436A1 (en) * 2014-06-23 2017-02-02 Bionomics, Inc. Antibodies that bind LGR4
US20180009869A1 (en) * 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
US20200362034A1 (en) * 2017-08-15 2020-11-19 Kindred Biosciences, Inc. IgG Fc Variants for Veterinary Use

Also Published As

Publication number Publication date
EP4004035A2 (en) 2022-06-01
KR20220071176A (en) 2022-05-31
CA3143785A1 (en) 2021-02-04
AU2020321376A1 (en) 2022-02-03
MX2022001104A (en) 2022-02-14
CN114466862A (en) 2022-05-10
BR112022000249A2 (en) 2022-05-17
EP4004035A4 (en) 2023-06-28
WO2021022067A3 (en) 2021-07-15
JP2022542275A (en) 2022-09-30
US20220267414A1 (en) 2022-08-25
WO2021022067A2 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
WO2021022067A8 (en) Parvovirus antibodies for veterinary use
CY1123791T1 (en) INTERLEUKIN-31 MONOCLONAL ANTIBODY
NZ704175A (en) Crystalline forms of 1-(5’-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3’h-spiro[azetidine-3,1’-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
EA201891499A1 (en) CHEMICAL DOG ANTI-CD20 ANTIBODY
TW200744632A (en) Use of alpha-toxin for treating and preventing staphylococcus infections
BRPI0413119A (en) use of optimized adcc antibodies to treat debilitated patients
WO2020082209A8 (en) Anti-cldn18.2 antibody and uses thereof
EA201592154A1 (en) METHOD OF IMPROVING LATENT HYDRAULIC AND / OR PUTZOLANE ACTIVITY OF MATERIALS
ATE540696T1 (en) ERBB2 ANTAGONISTS FOR TUMOR PAIN THERAPY
ATE488232T1 (en) P53 ACTIVATE BENZOYL UREA AND BENZOYLTHIOUREA COMPOUNDS
DE112019000752A5 (en) Coupling unit with torsional vibration damper as coupling carrier, hybrid module with coupling unit
CY1123046T1 (en) NON-HUMAN ANIMALS HAVING HUMANIZED FC-C RECEPTORS
AU2018254542A1 (en) IL4/IL13 receptor molecule for veterinary use
WO2019028182A3 (en) Cancer treatment using antibodies that bind human cd134 (ox40) receptor
WO2020076789A3 (en) Combinations of anti-staphylococcus aureus antibodies
CA187704S (en) Rail vehicle (part of -)
EP3766892A4 (en) Bismuth compound, curable composition, and cured body
EA201892323A1 (en) ADHESIVE COMPOSITION FOR ANTI-CORROSION PRODUCT
JP2015107959A5 (en) Composition in which isoxazoline compound is dispersed in polymer compound
EA202190538A1 (en) METHODS, PRODUCTS AND APPLICATIONS RELATED TO ACIDIC SULFIDE COMPOUNDS TRAPPING
DE112019000755A5 (en) Coupling unit with torsional vibration damper as coupling carrier, hybrid module with coupling unit
MX2022002360A (en) Anti-il31 antibodies for veterinary use.
AR099629A1 (en) A HETEROGENIC INSEMINATION PRODUCT
EP3162866A3 (en) Adhesive, use of an adhesive and method exclusively designed for cold foil finishing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20847060

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3143785

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022000249

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022505401

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020321376

Country of ref document: AU

Date of ref document: 20200730

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112022000249

Country of ref document: BR

Free format text: - APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DAS PRIORIDADES US 62/880,650 DE 30/07/2019, US 62/968,970 DE 31/01/2020 E US 63/030,123 DE 26/05/2020 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTAS CONFORME O ART. 15 DA PORTARIA 39/2021. OS DOCUMENTOS APRESENTADOS NAO ESTAO TRADUZIDOS E AS DECLARACOES NAO CONTEM OS DADOS IDENTIFICADORES DAS PRIORIDADES.- COM BASE NA PORTARIA 405 DE 21/12/2020, SOLICITA-SE QUE SEJA APRESENTADO, EM ATE 60 (SESSENTA) DIAS, NOVO CONTEUDO DE LISTAGEM DE SEQUENCIA POIS O CONTEUDO APRESENTADO NA PETICAO NO 870220001458 DE 06/01/2022 NAO ESTA NO FORMATO ST.25. O CAMPO 151 ESTA FORA DO PADRAO. DEVERA SER

ENP Entry into the national phase

Ref document number: 2020847060

Country of ref document: EP

Effective date: 20220228

ENP Entry into the national phase

Ref document number: 112022000249

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220106